| Abstract |
【Abstract】Objective To investigate the anti schizophrenia drug olanzapine combined with therapeutic effects of simvastatin on lipid metabolism and the clinical effect of the patients. Methods Selected 48 patients with schizophrenia treated in our hospital from January 2012 to June 2015 were randomly divided into the group with the inclusion criteria,, including observation group (olanzapine + simvastatin) and control group (olanzapine) 24 each Example 8 weeks. Results Before treatment, two weeks, four weeks, eight weeks, PANSS scores between the two groups was not statistically significant (P> 0.05), for two weeks, four weeks, eight weeks, both groups showed decreased PANSS score a trend (P <0.05); before treatment, two groups of patients TG, TC, HDL-C, LDL-C, FPG, Fins, BMI was no significant difference (P> 0.05), after treatment, the observation group patients TG, TC, LDL-C, FPG, Fins were significantly lower than the control group (P <0.05); After 8 weeks of treatment, the control group of patients with TG, TC, LDL-C, FPG, Fins than before treatment significantly increased (P <0.05). Conclusion Olanzapine combined with simvastatin in patients with schizophrenia will not affect the treatment effect, and can effectively reduce the olanzapine treatment process caused by lipids, blood glucose metabolism.
|